✦ LIBER ✦

Phase I/II study of treatment with matured dendritic cells with or without low dose IL-2 in patients with disseminated melanoma

✍ Scribed by P. Hersey; G. M. Halliday; M. L. Farrelly; C. DeSilva; M. Lett; S. W. Menzies

Publisher: Springer-Verlag
Year: 2007
Tongue: English
Weight: 577 KB
Volume: 57
Category: Article
ISSN: 0340-7004
DOI: 10.1007/s00262-007-0435-8

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I/II study of treatment with dendr

Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma

✍ Peter Hersey; ScottW. Menzies; GaryM. Halliday; Tam Nguyen; MargaretL. Farrelly; 📂 Article 📅 2004 🏛 Springer-Verlag 🌐 English ⚖ 214 KB

Phase I/II study of sequential chemoimmu

Phase I/II study of sequential chemoimmunotherapy (SCIT) for metastatic melanoma: outpatient treatment with dacarbazine, granulocyte-macrophage colony-stimulating factor, low-dose interleukin-2, and interferon-alpha

✍ Gerard Groenewegen; Andries Bloem; Gijsbert C. de Gast 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 268 KB

Hyperthermia for the treatment of patien

Hyperthermia for the treatment of patients with malignant germ cell tumors : A Phase I/II study in ten children and adolescents with recurrent or refractory tumors

✍ Rüdiger Wessalowski; Heidi Kruck; Hildegard Pape; Thomas Kahn; Reinhart Willers; 📂 Article 📅 1998 🏛 John Wiley and Sons 🌐 English ⚖ 151 KB 👁 3 views

waves in combination with platinum-based chemotherapy in ten children and 4 Institute of Statistics, Heinrich-Heine Univeradolescents with recurrent or refractory GCTs. sity, Du ¨sseldorf, Germany. ## RESULTS. Seven of ten patients with recurrent or refractory GCTs had objective responses. Of the

Phase I/II study of adoptive transfer of

Phase I/II study of adoptive transfer of γδ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma

✍ Hirohito Kobayashi; Yoshimasa Tanaka; Junji Yagi; Nagahiro Minato; Kazunari Tana 📂 Article 📅 2011 🏛 Springer-Verlag 🌐 English ⚖ 674 KB

Prolonged low dose IL-2 and thalidomide

Prolonged low dose IL-2 and thalidomide in progressive metastatic renal cell carcinoma with concurrent radiotherapy to bone and/or soft tissue metastasis: a phase II study

✍ J. M. Kerst; A. Bex; H. Mallo; L. Dewit; J. B. A. G. Haanen; W. Boogerd; H. J. T 📂 Article 📅 2005 🏛 Springer-Verlag 🌐 English ⚖ 293 KB

Interferon-α-2a with or without 13-cis r

Interferon-α-2a with or without 13-cis retinoic acid in patients with progressive, measurable metastatic renal cell carcinoma : Results of a randomized Phase II study (European Organization for Research and Treatment of Cancer Study 30951)

✍ Sophie D. Fosså; Gerald H. J. Mickisch; Pieter H. M. De Mulder; Simon Horenblas; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 English ⚖ 130 KB

## Background: In patients with metastatic renal cell carcinoma (mrcc), interferon-alpha (ifn) monotherapy leads to response rates of 5-15%, dependent on the selection of patients. in 1995, preclinical and clinical data indicated an improvement of these results if ifn was combined with 13-cis retin